Interaction of 2-Gy equivalent dose and margin status in perioperative high-dose-rate brachytherapy

Int J Radiat Oncol Biol Phys. 2011 Mar 15;79(4):1158-63. doi: 10.1016/j.ijrobp.2009.12.023.

Abstract

Purpose: To determine patient, tumor, and treatment factors predictive of local control (LC) in a series of patients treated with either perioperative high-dose-rate brachytherapy (PHDRB) alone (Group 1) or with PHDRB combined with external-beam radiotherapy (EBRT) (Group 2).

Patient and methods: Patients (n = 312) enrolled in several PHDRB prospective Phase I-II studies conducted at the Clínica Universidad de Navarra were analyzed. Treatment with PHDRB alone, mainly because of prior irradiation, was used in 126 patients to total doses of 32 Gy/8 b.i.d. or 40 Gy/10 b.i.d. treatments after R0 or R1 resections. Treatment with PHDRB plus EBRT was used in 186 patients to total doses of 16 Gy/4 b.i.d. or 24 Gy/6 b.i.d. treatments after R0 or R1 resections along with 45 Gy of EBRT with or without concomitant chemotherapy.

Results: No dose-margin interaction was observed in Group 1 patients. In Group 2 patients there was a significant interaction between margin status and 2-Gy equivalent (Eq2Gy) dose (p = 0.002): (1) patients with negative margins had 9-year LC of 95.7% at Eq2Gy = 62.9Gy; (2) patients with close margins of >1 mm had 9-year LC of 92.4% at Eq2Gy = 72.2Gy, and (3) patients with positive/close <1-mm margins had 9-year LC of 68.0% at Eq2Gy = 72.2Gy.

Conclusions: Two-gray equivalent doses ≥70 Gy may compensate the effect of close margins ≥1 mm but do not counterbalance the detrimental effect of unfavorable (positive/close <1 mm) resection margins. No dose-margin interaction is observed in patients treated at lower Eq2Gy doses ≤50 Gy with PHDRB alone.

Publication types

  • Clinical Trial, Phase I
  • Clinical Trial, Phase II

MeSH terms

  • Adolescent
  • Adult
  • Age Factors
  • Aged
  • Aged, 80 and over
  • Brachytherapy / methods*
  • Child
  • Dose Fractionation, Radiation
  • Female
  • Genital Neoplasms, Female / mortality
  • Genital Neoplasms, Female / pathology
  • Genital Neoplasms, Female / radiotherapy
  • Genital Neoplasms, Female / surgery
  • Head and Neck Neoplasms / mortality
  • Head and Neck Neoplasms / pathology
  • Head and Neck Neoplasms / radiotherapy
  • Head and Neck Neoplasms / surgery
  • Humans
  • Male
  • Middle Aged
  • Neoplasm Recurrence, Local / mortality
  • Neoplasm Recurrence, Local / pathology
  • Neoplasm Recurrence, Local / radiotherapy
  • Neoplasms / mortality
  • Neoplasms / pathology*
  • Neoplasms / radiotherapy*
  • Neoplasms / surgery
  • Prospective Studies
  • Sarcoma / mortality
  • Sarcoma / pathology
  • Sarcoma / radiotherapy
  • Sarcoma / surgery
  • Sex Factors
  • Tumor Burden
  • Young Adult